Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Cambrex Corp (CBM) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,612,320
  • Shares Outstanding, K 32,150
  • Annual Sales, $ 433,330 K
  • Annual Income, $ 57,220 K
  • 36-Month Beta 1.95
  • Price/Sales 3.91
  • Price/Book 4.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.15 +9.03%
on 11/23/16
53.65 -2.14%
on 11/14/16
+1.69 (+3.33%)
since 11/09/16
3-Month
38.30 +37.08%
on 11/03/16
53.65 -2.14%
on 11/14/16
+7.35 (+16.28%)
since 09/09/16
52-Week
29.50 +77.97%
on 02/08/16
59.41 -11.63%
on 07/21/16
+1.10 (+2.14%)
since 12/09/15

Most Recent Stories

More News
Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery

Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).

Why Syndax Pharmaceuticals (SNDX) Could Be Positioned for a Slump

Syndax Pharmaceuticals (SNDX) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.

Zacks.com featured highlights: Stamps.com, Gibraltar Industries, FutureFuel and Cambrex

Zacks.com featured highlights: Stamps.com, Gibraltar Industries, FutureFuel and Cambrex

Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place

Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place

AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

Is Cooper Companies (COO) Poised for Earnings Beat in Q4?

The Cooper Companies Inc. (COO) is set to report fourth-quarter fiscal 2016 results after the market closes on Dec 8.

Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

Juno Reports Positive Phase I Study Data on Lymphoma Drug

Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma...

Explosive Returns with the Filtered Zacks Rank 5 Strategy

Explosive Returns with the Filtered Zacks Rank 5 Strategy

Explosive Returns with the Filtered Zacks Rank 5 Strategy

Explosive Returns with the Filtered Zacks Rank 5 Strategy

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Business Summary

Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance...

See More

Support & Resistance

2nd Resistance Point 53.93
1st Resistance Point 53.22
Last Price 52.50
1st Support Level 51.97
2nd Support Level 51.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.